Research from Redeye, Redeye AB

Redeye

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen). 

Expertise in Denmark, Finland, Norway and Sweden.

Research from Redeye

Redeye AB

Specialists in innovative and fast-growing Nordic companies within Life Science and Technology.

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen).

Equity Bottom-Up

<ul><li>Redeye comments on Alzinova’s announcement that the FDA has approved its IND application for ALZ-101.</li><li>We view this regulatory clearance as an important milestone that enables the company to advance into phase II, strengthening the credibility of the program and paving the way for broader clinical evaluation.</li><li>The focus now shifts to securing a partnership and financing to ensure the study can commence on schedule.</li></ul>

Redeye comments on Alzinova’s announcement that the FDA has approved its IND application for ALZ-101.We view this regulatory clearance as an important milestone that enables the company to advance into phase II, strengthening the credibility of the program and paving the way for broader clinical evaluation.The focus now shifts to securing a partnership and financing to ensure the study can commence on schedule.

Alzinova: IND approval for phase II study